Magstim announced today that it received FDA clearance for its Horizon 3.0 transcranial magnetic stimulation (TMS) system with StimGuide Pro.
The latest platform builds on the previous H 3.0 system for treating patients with depressive or obsessive-compulsive conditions.
Horizon 3.0 with StimGuie Pro is the first integrated TMS system with navigation, Magstim said in a news release. It includes new advanced camera technology and software designed to allow for precise treatment targeting.
The system centralizes all patient treatments and technology on one screen to reduce complexity as well. It also has a Bluetooth anatomical pointer for mapping and treating patients.
Non-invasive TMS uses an electromagnetic coil to stimulate nerve cells in the brain region involved in mood control and depression. StimGuide Pro’s advanced navigation improves coil positioning for repeatability and accuracy. New camera and navigation workflow ensures magnetic pulses go to targeted brain regions, improving outcomes.
Magstim says its Magstim Connect feature enables the management of multiple systems from one central system, too.
“We are passionate about helping patients worldwide to improve their mental health,” said Ronnie Stolec-Campo, CEO, Magstim. “We worked with leading psychiatrists, clinicians, and researchers to develop this system, enabling advanced treatments and simplified practice workflows. TMS is life-saving technology that provides non-pharmacological, non-invasive treatments.”